Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $13.00.

Several equities analysts have issued reports on the stock. B. Riley Financial decreased their price target on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Orchestra BioMed in a report on Friday, July 17th. Piper Sandler reissued an “overweight” rating and issued a $10.00 price objective (up from $9.00) on shares of Orchestra BioMed in a research note on Tuesday, August 11th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Orchestra BioMed in a report on Thursday, May 14th. Finally, Barclays increased their price objective on Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th.

Insider Activity at Orchestra BioMed

In other Orchestra BioMed news, insider Darren Sherman sold 15,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $4.09, for a total value of $61,350.00. Following the sale, the insider owned 1,154,327 shares in the company, valued at approximately $4,721,197.43. The trade was a 1.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Orchestra BioMed

Hedge funds have recently bought and sold shares of the company. AXQ Capital LP bought a new position in Orchestra BioMed during the second quarter worth $110,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Orchestra BioMed during the second quarter valued at $2,771,000. Bank of America Corp DE bought a new stake in Orchestra BioMed during the second quarter valued at $103,000. Flat Footed LLC acquired a new stake in Orchestra BioMed during the 2nd quarter worth about $1,084,670,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Orchestra BioMed during the 2nd quarter worth about $91,000. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Stock Performance

NASDAQ:OBIO opened at $5.36 on Friday. The stock’s 50-day moving average is $4.16 and its 200-day moving average is $4.16. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.78. The company has a current ratio of 8.26, a quick ratio of 8.24 and a debt-to-equity ratio of 1.80. The stock has a market cap of $322.14 million, a P/E ratio of -6.31 and a beta of 0.50.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. Orchestra BioMed had a negative net margin of 184.60% and a negative return on equity of 149.61%. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.14 million. Equities research analysts anticipate that Orchestra BioMed will post -1.53 earnings per share for the current year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.